AFFILIATIONS
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 Boston Medical Center, Boston, Massachusetts, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 New York-Presbyterian/Weill Cornell Medical Center, New York, New York, United States
5 Medial College of Wisconsin, Milwaukee, Wisconsin, United States
6 Harvard Medical school, Boston, Massachusetts, United States
7 Harvard Medical school, Boston, Massachusetts, United States
8 University of Missouri School of Medicine, Columbia, Missouri, United States
9 University of Texas McGovern Medical School, Houston, Texas, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
15 Boston Medical Center, Boston, Massachusetts, United States
16 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Background: Adjuvant endocrine therapy for hormone receptor–positive breast cancer commonly includes tamoxifen or an aromatase inhibitor (AI). Tamoxifen is associated with an increased risk of venous thromboembolism (VTE), whereas AIs are not. However, tamoxifen remains an important treatment option, particularly for premenopausal women. At present, there is limited evidence to inform management of endocrine therapy once a VTE occurs. Consequently, we sought to explore thrombotic and bleeding outcomes in patients on endocrine therapy according to post-VTE endocrine therapy strategy.
Methods: We conducted a multicenter retrospective cohort study across four tertiary care institutions. Patients were included if they had breast cancer or ductal carcinoma in situ, received tamoxifen or an AI between January 2010 and December 2024, developed VTE while receiving endocrine therapy, and initiated anticoagulation. Potential patients were identified using International Classification of Diseases (ICD-9/10) codes, with eligibility and data confirmed by manual chart review. Patients with concurrent non-breast malignancy were excluded.
The first VTE episode during endocrine therapy was defined as the index event. The primary outcome was recurrent VTE, compared across post-VTE endocrine therapy groups: continuation of tamoxifen; continuation of an AI or transition from tamoxifen to an AI; or discontinuation of endocrine therapy. Secondary outcomes included major bleeding (ISTH-definition), arterial thrombosis, and death. Twelve-month cumulative incidence with 95% confidence intervals (CIs) was estimated for VTE, with death as a competing risk.
Results: The study cohort included 94 females (median age, 65 years [IQR, 54–73]); 68% were White, 25% African American, and 8% were of mixed or Asian ethnicity. Sixty-four percent of the cohort had stage I–II disease, while 16% had metastatic disease. Endocrine therapy was administered for a median of 26 months (IQR, 8–49) before the index VTE. Index events were most frequently pulmonary embolism (PE; n=54, 57.0%) followed by deep vein thrombosis (DVT; n=24, 25.4%). Two patients were on anticoagulation (both at reduced doses) at diagnosis of index VTE. At the time of index VTE, 55 patients (59%) were on an AI and 39 (42%) were taking tamoxifen. Following VTE, 43 (46%) individuals continued an AI, 9 (10%) transitioned from tamoxifen to an AI, 16 (17%) continued tamoxifen, and 26 (28%) discontinued or held endocrine therapy. Age differed across the post-VTE AI (continue/switch), tamoxifen (continue), and no endocrine therapy groups (median 68, 53, and 58 years, respectively; p<0.001). After VTE diagnosis, 91 patients (97%) received full-dose therapeutic anticoagulation and 2 (2%) received reduced-dose anticoagulation.
During the 12 months of follow-up, recurrent VTE occurred in 4 patients at a median of 118 days (interquartile range [IQR] 75-179), corresponding to a cumulative incidence of 4.6% (95% CI, 1.5-10%). All recurrent VTE events occurred in the post-VTE AI group, although the cumulative incidence did not differ significantly across groups (p=0.20). Two of the four recurrent VTEs occurred on anticoagulation, both at therapeutic doses. There was no statistically significant difference in anticoagulation discontinuation by 12 months across the post-VTE AI, tamoxifen, and no endocrine therapy groups (32%, 21%, and 48%, respectively; p=0.2).
Major bleeding occurred in 3 patients (3.2%) at a median of 24 days (IQR 17-72), including gastrointestinal (n=1), genitourinary (n=1), and retroperitoneal (n=1) bleeding. Arterial thrombosis occurred in 2 patients (2.1%). There were 3 patient deaths during follow-up (3.2%).
Conclusion: In this retrospective analysis, recurrent VTE was uncommon and did not differ significantly based on post-VTE endocrine therapy strategies. In fact, continuation of tamoxifen post-VTE was not associated with higher rates of VTE recurrence compared with discontinuation of endocrine therapy; however, the small number of events and baseline differences between groups limited adjustment for confounders. These findings suggest that endocrine therapy, including tamoxifen, may be continued in select patients receiving anticoagulation after VTE.
DISCLOSURES
Hila Ghersin, MD: No relevant conflicts of interest to declare.